疗养院居民中RSV疫苗对Medicare受益人的有效性
暴露为RSV疫苗接种,结局为RSV相关住院、死亡、严重结局(ICU/重症监护室入住、呼吸机使用或RSV相关死亡)及血栓栓塞事件。接种组相比未接种组,RSV相关住院VE为73%(95%CI 65%-79%),死亡VE为56%(95%CI 39%-69%),严重结局VE为59%(95%CI 44%-70%),血栓栓塞事件VE为66%(95%CI 44%-79%)。提示首个季节RSV疫苗与疗养院居民RSV相关结局改善相关。
要点
- 疗养院Medicare受益人接种RSV疫苗后,RSV相关住院风险降低73%(95%CI 65%-79%)。
- ≥75岁受益人住院VE为75%(95%CI 67%-82%),65-74岁为60%(95%CI 35%-76%)。
- 长期住院(≥100天)居民住院VE为80%(95%CI 68%-87%),短期住院(<100天)为67%(95%CI 55%-76%)。
- RSV相关死亡VE为56%(95%CI 39%-69%),严重RSV相关结局VE为59%(95%CI 44%-70%)。
- RSV相关血栓栓塞事件VE为66%(95%CI 44%-79%)。
适用人群与场景
- 纳入:年龄≥65岁、研究期间在美国疗养院居住至少1天、连续参加Medicare Part A和B(索引日期前365天)及Part D(自2023年6月21日起)的按服务收费受益人。
- 排除:原文未提及。
- 场景:疗养院居住的Medicare受益人,非急诊/ICU/院前特定场景。
诊断标准与关键阈值
- RSV诊断和结局定义基于带有相关ICD-10编码的索赔。
- RSV疫苗剂量通过国家药品代码目录从Medicare Part D索赔确定。
- 严重RSV相关结局定义:ICU或重症监护室入住、使用医疗呼吸机或RSV相关死亡。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 干预与对照:RSV疫苗接种 vs 未接种;主要终点:RSV相关住院。
- RSV相关住院VE为73%(95%CI 65%-79%);年龄65-74岁VE 60%(95%CI 35%-76%),≥75岁VE 75%(95%CI 67%-82%);短期住院(<100天)VE 67%(95%CI 55%-76%),长期住院(≥100天)VE 80%(95%CI 68%-87%)。
- 关键次要终点:RSV相关死亡VE 56%(95%CI 39%-69%);严重RSV相关结局VE 59%(95%CI 44%-70%);RSV相关血栓栓塞事件VE 66%(95%CI 44%-79%)。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:回顾性队列研究;证据等级或推荐强度:原文未提及。
- 局限:回顾性设计、基于索赔数据、单季节数据、观察性研究可能存在残余混杂,原文未提及单中心/多中心信息。
对床旁实践的改变
- 支持在疗养院居住的≥65岁Medicare受益人中接种RSV疫苗以降低RSV相关住院、死亡、严重结局及血栓栓塞事件风险。
- 适用人群:疗养院居住的≥65岁Medicare受益人;不适用人群:原文未提及。
- 常见陷阱:本研究为观察性设计,VE估计可能受混杂影响,不能推断因果关系;不适用于非疗养院居住人群。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Vaccine effectiveness (VE) estimates are needed to determine the effectiveness of respiratory syncytial virus (RSV) vaccinations during their first season of availability among populations at high risk for severe RSV.
OBJECTIVE: To assess RSV VE against RSV-associated outcomes for nursing home residents.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of Medicare fee-for-service beneficiaries used electronic medical claims data from September 10, 2023, to March 30, 2024. A cohort was created for each outcome: an RSV-associated hospitalization cohort; an RSV-associated death cohort; a severe RSV-associated outcome cohort; and an RSV-associated thromboembolic event cohort. To be eligible for inclusion in a cohort, a Medicare fee-for-service beneficiary must be aged 65 years or older, reside in a US nursing home during the study period for at least 1 day, have continuous enrollment in Medicare Parts A and B (365 days prior to the index date), and have continuous enrollment in Part D (beginning on June 21, 2023).
EXPOSURE: RSV vaccination.
MAIN OUTCOMES AND MEASURES: Outcomes were RSV-associated hospitalization, RSV-associated death, severe RSV-associated outcomes (intensive care unit or critical care unit admission, medical ventilator use, or RSV-associated death), and RSV-associated thromboembolic event. RSV diagnoses and outcome definitions were based on claims with relevant International Classification of Diseases and Related Health Problems, Tenth Revision codes. RSV vaccine doses were determined from Medicare Part D claims using the National Drug Code Directory. Hazard ratios (HRs) from multivariable Cox proportional hazards models compared the times to first outcomes among RSV vaccinated beneficiaries and unvaccinated beneficiaries. VE was calculated as (1-HR) × 100%.
RESULTS: Of 597 430 included Medicare beneficiaries (66% female; median age, 82 [IQR, 75-88] years), RSV VE against RSV-associated hospitalizations was 73% (95% CI, 65%-79%). Among beneficiaries aged 65 to 74 years VE was 60% (95% CI, 35%-76%), 75% (95% CI, 67%-82%) among beneficiaries 75 years or older, 67% (95% CI, 55%-76%) among short-stay residents (<100 cumulative days), and 80% (95% CI, 68%-87%) among long-stay residents (≥100 cumulative days). VE against RSV-associated death was 56% (95% CI, 39%-69%), VE against severe RSV-associated outcomes was 59% (95% CI, 44%-70%), and VE against RSV-associated thromboembolic events was 66% (95% CI, 44%-79%).
CONCLUSIONS AND RELEVANCE: In this study, in the first season of availability, RSV vaccines were associated with improved RSV-associated outcomes among US Medicare beneficiaries residing in nursing homes.
参考来源
- Wiegand RE, Sung HM, Zhang Y, et al. Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing Homes. JAMA Intern Med. 2026. PMID: 42671854. doi:10.1001/jamainternmed.2026.3841
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。